Host cell proteins (HCPs) are the most important process-related impurity in recombinant biopharmaceuticals, ie proteins produced in bacteria, yeast, and mammalian cell lines. Limited by current purification techniques, low levels (1 to 100 ppm) of host cell proteins (HCPs) may still remain in the purified biotherapeutics, even after a series of purifications. The ppm-level residual host cell proteins may effect drug safety and efficacy and cause adverse effects in patients, and can impact stability of the drug substance by proteolytic activity, so they are required to be identified and quantified as part of drug safety evaluation, by the regulatory agencies.
In order to avoid clinical failures of your drug product, it is desperately needed to learn as much qualitative and quantitative information about host cell proteins in your samples as possible. Identification and quantification of host cell proteins allow risk evaluation of each individual host cell protein, and facilitate development of the manufacturing process to remove HCPs of concern.
Usually the HCP assay can be achieved by 2D Electrophoresis, Western Blot and ELISA. After efficient separation of the biotherapeutics with electrophoresis, the host cell proteins could be identified and quantified with antiserum or polyclonal antibodies. LC-MS/MS, as a powerful analytical technique, has been introduced for HCP profiling as a revolutionary technology in recent years.
Biotherapeutics regulatory agencies (FDA, EMA, etc) are increasingly aware of the importance of mass spectrometry as an orthogonal method to ELISA for host cell protein analysis as described in the European and US Pharmacopeia.
Complete Omics has been developing and providing HCP analysis services in the following areas:
1) Host cell protein analysis for biotherapeutics manufacturing pipeline optimization:
➢Identification of HCPs in each manufacturing step
➢Physical and Chemical properties of each HCP (poly-peptide sequence, molecular weight, pI, hydrophobicity, PTMs,)
➢Evaluate HCPs between manufacturing steps and identify/test the best protocol for HCP clearance
2) Host cell protein analysis for biotherapeutics products
➢Identification of HCPs in GMP batches, incorporated as a QC step for your product
➢Documentation of HCP detection and clearance for PAT and process validation
➢Absolute and relative quantification of specific HCPs, as accurate as protein copy number per ug product, eg. 1.3 million HCP protein copies per ug product.
3) Characterization and in-depth study of host cell protein of concern
➢Identification and quantification of HCPs of potential concern in drug substance
➢Characterization of your desired features of the identified HCPs
➢Development of the protocol to monitor and clear the HCPs based on your particular request
The protein therapeutics are separated with 1D/ 2D electrophoresis, and then visualized by Coomassie brilliant blue or sliver staining, and then digested into peptides by in-gel digestion for mass spectrometry analysis. Meanwhile, the protein therapeutics can be in-solution digested directly for nanoLC-ESI-LTQ/Orbitrap system. The contaminant proteins can be detected by database searching through numerous commercial softwares and can be de novo sequenced by our new PEAKS studio and Q module software platform. Complete Omics can help you select the best methods based on your biopharmaceuticals and FDA’s guidelines.
Data analysis, including data validation, visualization and quantification, are performed with commercial softwares and Complete Omics’ unique R packages and scripts. Report will be sent to you in Excel format as well as a summary in PDF format. We will also provide you any details you need for your papers’ MATERIALS AND METHODS section. We will make sure you understand your result and help you with your paper writing with free follow-up services.
Sample types we accept:
1, Customized sample types (please contact us to discuss)
Some of our impacts
2021--Direct Quantification of Neoantigens Like Never Before --- published on Science and Science ImmunologyGenetic changes in human genome are the driving force for all cancers. Different patients have different sets of mutation profiles even when the patients all have the same disease. For decades, doctors, cancer scientists, and pharmaceutical companies have been working tirelessly trying to find a way to treat each person's unique disease in a highly personalized way that will reach the maximum treatment efficacy with the lowest side effects. Complete Omics, working with leaders in cancer therapeutics, has developed two applications based on our Valid-NEO pipeline through which we clearly saw personalized therapeutic targets on the cancer cell surface before adopting a highly specific treatment, for here bispecific antibodies. Two papers describing our new technologies are puslished on Science (Ref. 1) and Science Immunology (Ref. 2). Our pipeline has been reported by GenomeWeb (Ref. 3)Prediction-FREE Neoantigen Validation Enables Personalized Cancer Therapeutics
2019--First Pipeline for Direct Detection and Quantification of NeoantigensCancer-linked genetic mutations can code for mutant proteins, which can then be processed by proteasomes into peptides that are presented by human leukocyte antigen (HLA) molecules, triggering the body's immune response. The idea that such mutant peptides can trigger an immune response is fundamental to immunotherapies like checkpoint inhibitors as well as cancer vaccines that present the body with these peptides to generate an immune reaction. However, while the rise of next-generation sequencing has allowed researchers to identify a large number of cancer-linked mutations, actually detecting these mutation-associated neo-antigens, or MANAs, at the peptide level remains difficult. The fact that a mutant is present at the genetic level does not mean it will be produced at the protein level, and, even if it is, that is no guarantee that it will be processed and presented by HLA molecules. This has proved a challenge for, for instance, personalized cancer vaccine development. Our technology (Ref. 1) provide the 1st pipeline for detecting personalized cancer therapeutic targets. Our method has been reported by public media and has a significant impact in cancer research (Ref. 2).Direct Detection and Quantification of Neoantigens
2017--First Pipeline for Proteomics-based Clinical DiagnosticsWe developed the 1st pipeline for discovering and validating proteomic biomarkers from patient plasma samples (Ref 1). With this pipeline, we identified an ovarian cancer biomarker, peptidyl-prolyl cis–trans isomerase A (PPIA), with zero false positive diagnostic value. Our finding was featured on Genomeweb (Ref 2). We quantified 318 peptides in 94 separate samples, 48 from healthy controls, 14 from colorectal cancer cases, 14 from ovarian cancer cases, and 18 from pancreatic cancer cases. We then analyzed this data to see if any of the peptides or combinations of the peptides allowed us to accurately identify their sample of origin, and in this way identified the two PPIA peptides as potential markers for ovarian cancer. We then measured these two peptides in a separate cohort of 73 cases consisting of 35 ovarian cancer cases and 14 healthy controls and 24 pancreatic cancer cases. One of the two peptides was detected in 20 of the 35 ovarian cancer plasma samples, while neither was detected in any of the healthy controls.SAFE-SRM and Ovarian Cancer Diagnostics
2016--Targeted sequencing of both DNA strands barcoded and captured individually by RNA probes to identify genome-wide ultra-rare mutations.Targeted sequencing has been an essential application in Next Generation Sequencing (NGS). However, all target capture commercial technologies on the market have relatively low capturing efficiencies. That being said, after utilizing those capture kits, instead of sequencing a sufficient number of unique molecules, you are actually sequecing a library of nucleic acid amplicons that are amplified from very few DNA molecules captured by those old commercial technologies from initial NGS library, and usually the fraction of molecules that can be captured and subsequently sequenced is less than 9% of the molecules from the initial NGS library. Due to the unsatisfying performance of current commercial capture kits and platforms, Complete Omics has been trying to develop its own target capture technologies, and finally we have something to show you. We believe that this new technology could potentially revolutionize NGS targeted sequencing field. We are proud to anounce DEEPER-Capture, the next generation target capture technology for NGS sequencing. In DEEPER-Capture both DNA strands from the same DNA duplex molecule are captured by a pair of complementary RNA probes, and sequenced, simutanously. Using DEEPER-Capture, we repeatedly achieved an over 3-fold higher capturing efficiency than the best performance ever observed from competing platforms reported by numerous labs.DEEPER-Seq: Capture both DNA strands with dual RNA probes
2010--Mutant Proteins As Cancer Specific BiomarkersCancer biomarkers are currently the subject of intense research because of their potential utility for diagnosis, prognosis, and targeted therapy. In theory, the gene products resulting from somatic mutations are the ultimate protein biomarkers, being not simply associated with tumors but actually responsible for tumorigenesis. In 2010, we developed the 1st pipeline for detecting and quantifying mutant protein as cancer specific biomarkers from human specimens, and it received a broad range of attentions from different disciplines of biomedical sciences [Ref. 1]. We demonstrated that altered protein products resulting from somatic mutations can be identified directly and quantified. As a prototypical example of this approach, we demonstrated that it is possible to quantify the number and fraction of mutant Ras protein present in cancer cell lines. There were an average of 1.3 million molecules of Ras protein per cell, and the ratio of mutant to normal Ras proteins ranged from 0.49 to 5.6. Similarly, we found that mutant Ras proteins could be detected and quantified in clinical specimens such as colorectal and pancreatic tumor tissues as well as in premalignant pancreatic cyst fluids. In addition to answering basic questions about the relative levels of genetically abnormal proteins in tumors, this approach lays the foundation for mutant protein-based cancer diagnostics.
Mutant Proteins As Cancer Specific Biomarkers
- Publication: Mutant proteins as cancer-specific biomarkers.